Anadys in Japanese collaboration
Anadys Pharmaceuticals and Aphoenix, an emerging chemical genomics company in Japan, have entered into a three-year drug discovery collaboration.
Anadys Pharmaceuticals and Aphoenix, an emerging chemical genomics company in Japan, have entered into a three-year drug discovery collaboration.
Under the terms of the agreement, Anadys will utilise its drug discovery capabilities to discover and advance lead compounds against Aphoenix targets in multiple therapeutic indications. Aphoenix has already established early stage drug discovery programs in respiratory and anti-inflammatory diseases.
'We are pleased to collaborate with Aphoenix in the pursuit of novel therapeutics,' said Dr Kleanthis Xanthopoulos, Anadys' president and ceo. 'By combining our expertise in lead generation with promising targets from Aphoenix, we look forward to ushering quality compounds into preclinical development. Additionally, we are pleased to participate in the potential downstream value of these programs.'
'Our reverse targeting capability coupled with Anadys' technologies and capabilities create a great synergy. This combination provides Aphoenix with an opportunity to realise a comprehensive chemical genomics approach,' said Dr Shingo Kano, Aphoenix's president and ceo. 'We are pleased to link value chains of such critical processes and leverage our target identification engine with Anadys.'